Ranok Therapeutics (Hangzhou)
Ranok Therapeutics (Hangzhou) is a China-based biotechnology company running 2 late-stage cancer trials of RNK08954-01 and RNK05047 in sarcomas and diffuse large B-cell lymphoma.
Overview
Ranok Therapeutics (Hangzhou), based in Hangzhou, China, is a biotechnology company. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing RNK08954-01 and RNK05047 in sarcomas and diffuse large B-cell lymphoma. The largest, NCT06667544 (A Study of RNK08954 in Subjects With Advanced Solid Tumours With KRAS ((Kirsten Rat Sarcoma) G12D Mutation), plans to enrol 152 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry, checked on 2026-09-11; company facts are from the official website.
Similar pages
not linked directly; found by shared links- CompanyQBiotics
Shares Sarcomas (soft tissue, bone, GIST) and the tag ctgov-sponsor.
- CompanyEpicentRx
Shares Sarcomas (soft tissue, bone, GIST) and the tag ctgov-sponsor.
- CompanyPhilogen S.p.A.
Shares Sarcomas (soft tissue, bone, GIST) and the tag ctgov-sponsor.
- CompanyHaihe Biopharma
Shares Sarcomas (soft tissue, bone, GIST) and the tag ctgov-sponsor.
- CompanyMiltenyi Biomedicine
Shares Diffuse large B-cell lymphoma and the tag ctgov-sponsor.
- CompanyKartos Therapeutics
Shares Diffuse large B-cell lymphoma and the tag ctgov-sponsor.
- CompanyOncoC4
Shares Sarcomas (soft tissue, bone, GIST) and the tag ctgov-sponsor.
- CompanySinocelltech
Shares Diffuse large B-cell lymphoma and the tag ctgov-sponsor.